Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Cancer Center, Korea |
---|---|
Information provided by: | National Cancer Center, Korea |
ClinicalTrials.gov Identifier: | NCT00532272 |
Primary objective is to evaluate the response rates and clinical benefits of letrozole + goserelin in premenopausal patients versus letrozole alone in postmenopausal patients with metastatic breast cancer as first line hormonal therapy
Condition | Intervention | Phase |
---|---|---|
Breast Cancer Metastatic |
Drug: Letrozole |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | A Phase II Non-Randomized, Parallel Group Study of Goserelin or Leuprorelin Plus Letrozole in Premenopausal Patients Versus Letrozole Alone in Postmenopausal Patients With Metastatic Breast Cancer |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Jungsil Ro, MD, PhD | 82-31-920-1610 | jungsro@ncc.re.kr |
Korea, Republic of | |
National Cancer Center | Recruiting |
Goyang, Korea, Republic of |
Principal Investigator: | Jungsil Ro, MD,PhD | National Cancer Center, Korea |
Study ID Numbers: | NCCCTS-05-149 |
Study First Received: | September 19, 2007 |
Last Updated: | September 19, 2007 |
ClinicalTrials.gov Identifier: | NCT00532272 History of Changes |
Health Authority: | South Korea: Institutional Review Board |
Skin Diseases Goserelin Breast Neoplasms |
Letrozole Aromatase Inhibitors Breast Diseases |
Neoplasms Neoplasms by Site Molecular Mechanisms of Pharmacological Action Skin Diseases Antineoplastic Agents Therapeutic Uses |
Breast Neoplasms Enzyme Inhibitors Letrozole Aromatase Inhibitors Pharmacologic Actions Breast Diseases |